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Background
Th e role of stress-dose hydrocortisone in the manage-
ment of trauma patients is currently unknown.
Methods
Objective: To test the eﬃ  cacy of hydrocortisone therapy 
in trauma patients.
Design: Multicenter randomized, double blind, placebo-
controlled study.
Setting: Seven intensive care units (ICUs) in France 
during November 2006 to August 2009.
Subjects: 150 patients with severe trauma who required 
ICU stay for at least 48 hours were included in the study.
Intervention: Patients were randomly assigned to a 
continuous intravenous infusion of either hydrocortisone 
(200 mg/day for 5 days, followed by 100 mg on day 6 and 
50 mg on day 7) or placebo. Th e treatment was stopped if 
patients had an appropriate adrenal response.
Outcomes: Hospital-acquired pneumonia within 28 days. 
Secondary outcomes included the duration of mechanical 
ventilation, ICU length of stay, hyponatremia, and death.
Results
An intention-to-treat (ITT) analysis included 149 
patients and the modiﬁ ed ITT analysis included 113 
patients with corticosteroid insuﬃ  ciency. In the ITT 
analysis, 26 of 73 patients (35.6%) treated with hydro-
cortisone and 39 of 76 patients (51.3%) receiving placebo 
developed hospital-acquired pneumonia by day 28 
(hazard ratio (HR), 0.51; 95% conﬁ dence interval (CI), 
0.30-0.83; P = 0.007). In the modiﬁ ed ITT analysis, 20 of 
56 patients (35.7%) in the hydrocortisone group and 31 of 
57 patients (54.4%) in the placebo group developed 
hospital-acquired pneumonia by day 28 (HR, 0.47; 95% 
CI, 0.25-0.86; P = 0.01). Mechanical ventilation–free days 
increased with hydrocortisone use by 4 days (95% CI, 2-7; 
P = 0.001) in the ITT analysis and 6 days (95% CI, 2-11; 
P  <  0.001) in the modiﬁ ed ITT analysis. Hyponatremia 
was observed in 7 of 76 (9.2%) in the placebo group vs. 
none in the hydrocortisone group (absolute diﬀ erence, 
−9%; 95% CI, −16% to −3%; P = 0.01). Four of 76 patients 
(5.3%) in the placebo group and 6 of 73 (8.2%) in the 
hydrocortisone group died (absolute diﬀ erence, 3%; 95% 
CI, −5% to 11%; P = 0.44).
Conclusions
In intubated trauma patients, the use of an intravenous 
stress-dose of hydrocortisone, compared with placebo, 
resulted in a decreased risk of hospital-acquired pneumonia.
Commentary
Severe trauma is a leading cause of death, especially in 
younger adults. Patients who survive the initial trauma 
are at high risk for infections, which often increases 
subsequent morbidity and mortality. Pneumonia is a 
common infection, occurring in 40-60% of trauma 
patients. Shock and resuscitation following trauma may 
lead to an exaggerated immune response [1]. Th e “two hit 
hypothesis” states that an initial less severely injured 
patient may eventually develop worsening of multi-organ 
failure as a result of reactivation of their inﬂ ammatory 
response due to minor intercurrent event [2], such as an 
infection. Th us, preventing infection in trauma patients is 
important.
Th e eﬀ ect of glucocorticoid therapy on susceptibility to 
infections is controversial. Several lines of evidence 
suggest that glucocorticoid therapy may reduce risk of 
infection. For example, higher circulating levels of pro-
inﬂ ammatory cytokines, such as tumor necrosis factor 
(TNF) and interleukin (IL)-6, may increase risk of © 2010 BioMed Central Ltd
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infection in animal models and human studies [3,4]. 
Gluco corticoids inhibit nuclear factor-kB and trans crip-
tion of genes that code for pro-inﬂ ammatory cytokines, 
includ ing TNF, IL-1, IL-6, IL-8, and interferon (IFN)-γ 
[5,6], and may therefore prevent infection. Th e acute pro-
inﬂ ammatory response following trauma is followed by a 
compensatory anti-inﬂ ammatory response, where immune 
cells may experi ence tolerance (immuno paralysis). 
Although immuno paralysis may be important to dampen 
the deleterious eﬀ ects of the pro-inﬂ ammatory response, 
patients may be at higher risk for secondary infections 
during this phase. By reducing the early inﬂ ammatory 
response, gluco corticoids may reduce the magnitude of 
the subse quent anti-inﬂ ammatory response, thereby 
reduc ing risk of secondary infections. However, some 
studies suggest that glucocorticoid therapy could have 
deleter ious eﬀ ects on infection risk. For instance, the risk 
of secondary infections was higher in patients who 
received gluco corticoid therapy in the CORTICUS [7] 
trial. No large randomized clinical trial has examined the 
eﬃ  cacy of glucocorticoids to prevent infections and the 
current study by Roquilly et al. remains one of the largest 
studies to test this hypothesis.
In this study the author enrolled 150 patients with an 
injury severity score of 15 and above and included 
patients with traumatic brain injury (managed at a level 1 
trauma center) and randomized them to cortisol and 
placebo treated arms. Baseline cortisol was measured 
and patients who were cortisol-deﬁ cient were given 
steroid treatment for 1  week. Th e author determined 
occurrence of pneumonia within 28 days of hospitali za-
tion and found that patient who received steroid treat-
ment had a signiﬁ cantly lower incidence of pneumonia 
compared to placebo (HR, 0.51; P = 0.007).
Th e results of this study are in contrast with the results 
of the CRASH [8] study. Th e CRASH study was a large 
multicenter randomized clinical trial conducted in 10,000 
patients with head injury, as evidenced by Glasgow Coma 
Score of 14 or less, to determine whether high dose 
glucocorticoids improve outcomes. However, there were 
important diﬀ erences between the HYPOLYTE and 
CRASH studies (Table 1). In contrast to CRASH, which 
focused on traumatic head injury patients alone, 
HYPOLYTE enrolled a broad population of patients with 
trauma and included a smaller subset (44.96%) with head 
injury. Both dose and duration of glucocorticoid therapy 
were diﬀ erent. CRASH used high dose steroids, which 
may lead to immunosuppression. HYPOLYTE used low-
moderate dose glucocorticoids, which are less likely to 
cause immune suppression and may be important in 
patients who have critical illness-related corticosteroid 
insuﬃ  ciency (CIRCI). Th e CRASH study treated all 
patients with glucocorticoid therapy, whereas the 
HYPOLYTE study discontinued therapy in those who did 
not meet criteria for relative adrenal insuﬃ  ciency. Dura-
tion of therapy also diﬀ ered between these studies and 
shorter course of steroids can be associated with rebound 
inﬂ ammation. Finally, the primary endpoint in these 
studies was also diﬀ erent. For example, the primary end-
point was all-cause mortality at 2  weeks in the CRASH 
study, whereas the HYPOLYTE study examined eﬀ ect of 
steroids on hospital-acquired pneumonia. Th e CRASH 
study was stopped early due to higher mortality in the 
steroid treated arm, whereas the current study showed 
no diﬀ erence in mortality between the two treat ment 
groups.
Th is study by Roquilly et al. has several limitations. 
First, cortisol levels drawn prior to administering steroids 
may be inﬂ uenced by the prior use of etomidate for 
intubation, (63% of patients in this study received 
etomidate prior to intubation), which can cause adrenal 
suppression for approximately 24 hours [9,10]. Th us, the 
high rate of adrenal insuﬃ  ciency may be inﬂ uenced by 
etomidate administration. Second, it is unclear whether 
steroid therapy should be targeted based on presence or 
absence of relative adrenal insuﬃ  ciency. Although the 
corticotropin stimulation test is recommended to 
diagnose CIRCI, results of the CORTICUS trial showed 
no diﬀ erence in the eﬃ  cacy of glucocorticoid therapy 
among those with and without relative adrenal insuﬃ  -
ciency. Th ird, the investigators did not assess the long-
term eﬀ ects of steroid use, such as myopathy and critical 
illness neuropathy, a potential complication of gluco-
corticoid therapy. Finally, the study did not determine 
mechanisms of beneﬁ cial eﬀ ects of steroids. For example, 
whether steroids reduced risk of infection by reducing 
pro-inﬂ ammatory markers or improved immune cell 
function is not known.
Recommendation
Although results of this study are intriguing, gluco-
corticoids cannot be recommended for routine use in 
trauma patients. Th ese results suggest a nee d to con duct 
a larger trial to understand whether a reduction in 
infection observed in this study translates into improved 
mortality.
Table 1. Diff erences between HYPOLYTE and CRASH 
studies
 CRASH STUDY HYPOLYTE STUDY
Number of patients 10,000 150
Primary end point Mortality Pneumonia incidence
Time to administration of  < 8 hours Within 36 hours of
fi rst dose of steroid  trauma; 25 hours 
  (median)
Steroid loading dose 2 gms None
Duration of Steroids 48 hours 1 week
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